Welcome to LookChem.com Sign In|Join Free
  • or
1,2-Benzenediamine, N-[2-(1-piperidinyl)ethyl]- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

5625-68-3

Post Buying Request

5625-68-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5625-68-3 Usage

Chemical Structure

1,2-Benzenediamine, N-[2-(1-piperidinyl)ethyl]-

Classification

Chemical compound

Derivative of

Piperidine

Usage

Synthesis of pharmaceuticals

Building Block

Creation of various drugs

Potential Drug Candidate

Treatment of neurological disorders and cancer

Biological Activities

Strong

Therapeutic Effects

Central nervous system

Field of Application

Medicinal chemistry

Purpose

Development of new drug molecules

Check Digit Verification of cas no

The CAS Registry Mumber 5625-68-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,6,2 and 5 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 5625-68:
(6*5)+(5*6)+(4*2)+(3*5)+(2*6)+(1*8)=103
103 % 10 = 3
So 5625-68-3 is a valid CAS Registry Number.

5625-68-3Downstream Products

5625-68-3Relevant academic research and scientific papers

Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[ a[phenazin derivatives as dual topoisomerase I/II inhibitors

Yao, Bing-Lei,Mai, Yan-Wen,Chen, Shuo-Bin,Xie, Hua-Ting,Yao, Pei-Fen,Ou, Tian-Miao,Tan, Jia-Heng,Wang, Hong-Gen,Li, Ding,Huang, Shi-Liang,Gu, Lian-Quan,Huang, Zhi-Shu

, p. 540 - 553 (2015/01/30)

A novel series of benzo[a]phenazin derivatives bearing alkylamino side chains were designed, synthesized and evaluated for their topoisomerases inhibitory activity as well as cytotoxicity against four human cancer cell lines (HL-60, K-562, HeLa, and A549)

BICYCLIC HETEROCYCLES CAPABLE OF MODULATING T-CELL RESPONSES, AND METHODS OF USING SAME

-

, (2014/01/07)

The present disclosure is directed in part to bicyclic heterocycles, such as a compound represented by formula (I) or (II) as disclosed herein, and their use in treating medical disorders, such as immune inflammatory disorders such as Crohn's disease, ulc

Benzimidazole and imidazole inhibitors of histone deacetylases: Synthesis and biological activity

Bressi, Jerome C.,Jong, Ron de,Wu, Yiqin,Jennings, Andy J.,Brown, Jason W.,O'Connell, Shawn,Tari, Leslie W.,Skene, Robert J.,Vu, Phong,Navre, Marc,Cao, Xiaodong,Gangloff, Anthony R.

scheme or table, p. 3138 - 3141 (2010/09/03)

A series of N-hydroxy-3-[3-(1-substituted-1H-benzoimidazol-2-yl)-phenyl]-acrylamides (5a-5ab) and N-hydroxy-3-[3-(1,4,5-trisubstituted-1H-imidazol-2-yl)-phenyl]-acrylamides (12a-s) were designed, synthesized, and found to be nanomolar inhibitors of human histone deacetylases. Multiple compounds bearing an N1-piperidine demonstrate EC50s of 20-100 nM in human A549, HL60, and PC3 cells, in vitro and in vivo hyperacetylation of histones H3 and H4, and induction of p21waf. Compound 5x displays efficacy in human tumor xenograft models.

Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening

Holloway, Georgina A.,Baell, Jonathan B.,Fairlamb, Alan H.,Novello, Patrizia M.,Parisot, John P.,Richardson, John,Watson, Keith G.,Street, Ian P.

, p. 1422 - 1427 (2007/10/03)

A high-throughput screening campaign of a library of 100,000 lead-like compounds identified 2-iminobenzimidazoles as a novel class of trypanothione reductase inhibitors. These 2-iminobenzimidazoles display potent trypanocidal activity against Trypanosoma

Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors

Dudash Jr., Joseph,Zhang, Yongzheng,Moore, John B.,Look, Richard,Liang, Yin,Beavers, Mary Pat,Conway, Bruce R.,Rybczynski, Philip J.,Demarest, Keith T.

, p. 4790 - 4793 (2007/10/03)

A series of 3-anilino-quinoxalinones has been identified as a new class of glycogen phosphorylase inhibitors. The lead compound 1 was identified through high throughput screening as well as through pharmacophore-based electronic screening. Modifications were made to the scaffold of 1 to produce novel analogues, some of which are 25 times more potent than the lead compound.

ARYL SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS SODIUM CHANNEL BLOCKERS

-

Page 25, (2008/06/13)

This invention relates aryl substituted benzimidazoles of Formula (I), or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein R1, R2, R10 and n are defined in the specification. The invention is also di

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 5625-68-3